{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:53:28Z","timestamp":1775058808401,"version":"3.50.1"},"reference-count":54,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15023","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T12:01:21Z","timestamp":1744027281000},"page":"1-11","source":"Crossref","is-referenced-by-count":4,"title":["Durvalumab\u2011induced type 1 diabetes mellitus in lung adenocarcinoma: A case report and literature review"],"prefix":"10.3892","volume":"29","author":[{"given":"Huijing","family":"Dong","sequence":"first","affiliation":[{"name":"China\u2011Japan Friendship Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100029, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengfu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Tai Yuan Fourth Peoples (Tuberculosis) Hospital, Taiyuan, Shanxi 030053, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmei","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Fangshan Hospital Beijing University of Chinese Medicine, Beijing 102400, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[{"name":"China\u2011Japan Friendship Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100029, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiabin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Integrative Oncology, China\u2011Japan Friendship Hospital, Beijing 100029, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongxiang","family":"Xue","sequence":"additional","affiliation":[{"name":"China\u2011Japan Friendship Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100029, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumin","family":"Zheng","sequence":"additional","affiliation":[{"name":"China\u2011Japan Friendship Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100029, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixuan","family":"Yu","sequence":"additional","affiliation":[{"name":"China\u2011Japan Friendship Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100029, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingyu","family":"Lu","sequence":"additional","affiliation":[{"name":"China\u2011Japan Friendship Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100029, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixin","family":"Hu","sequence":"additional","affiliation":[{"name":"China\u2011Japan Friendship Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100029, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Integrative Oncology, China\u2011Japan Friendship Hospital, Beijing 100029, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"key20250513102021_b1-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"key20250513102021_b2-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"key20250513102021_b3-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20250513102021_b4-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): Diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"key20250513102021_b5-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11912-018-0671-4","article-title":"Incidence and management of immune-related adverse events in patients undergoing treatment with immune checkpoint inhibitors","volume":"20","author":"Kottschade","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"key20250513102021_b6-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"e00505","DOI":"10.1002\/edm2.505","article-title":"Immune checkpoint Inhibitors-induced endocrinopathies: Assessment, management and monitoring in a comprehensive cancer centre","volume":"7","author":"Elshafie","year":"2024","journal-title":"Endocrinol Diabetes Metab"},{"key":"key20250513102021_b7-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"key20250513102021_b8-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.2337\/dc20-0459","article-title":"Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015\u20132019","volume":"43","author":"Liu","year":"2020","journal-title":"Diabetes Care"},{"key":"key20250513102021_b9-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00592-018-1234-8","article-title":"Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: Description of pancreatic endocrine and exocrine phenotype","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol"},{"key":"key20250513102021_b10-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.3390\/jcm13216322","article-title":"The Double-edged sword of Immunotherapy-Durvalumab-induced Polyendocrinopathy-case report","volume":"13","author":"B\u0142a\u017cowska","year":"2024","journal-title":"J Clin Med"},{"key":"key20250513102021_b11-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20250513102021_b12-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: Management of Immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"key20250513102021_b13-ol-29-6-15023","first-page":"8781347","article-title":"Immune checkpoint inhibitor induced diabetes mellitus treated with insulin and metformin: Evolution of diabetes management in the era of immunotherapy","volume":"2019","author":"Alrifai","year":"2019","journal-title":"Case Rep Oncol Med"},{"key":"key20250513102021_b14-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"2017220999","DOI":"10.1136\/bcr-2017-220999","article-title":"New onset diabetes after nivolumab treatment","volume":"2018","author":"Capitao","year":"2018","journal-title":"BMJ Case Rep"},{"key":"key20250513102021_b15-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00262-016-1913-7","article-title":"A case of Pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes","volume":"66","author":"Chae","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"key20250513102021_b16-ol-29-6-15023","first-page":"e8836","article-title":"Pembrolizumab: An immunotherapeutic agent causing endocrinopathies","volume":"12","author":"Chaudry","year":"2020","journal-title":"Cureus"},{"key":"key20250513102021_b17-ol-29-6-15023","first-page":"21","article-title":"New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer","volume":"2022","author":"Cunha","year":"2022","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"key20250513102021_b18-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: A case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"key20250513102021_b19-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1177\/1078155220943949","article-title":"New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature","volume":"27","author":"Delasos","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"key20250513102021_b20-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/1759-7714.13065","article-title":"Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an Immune-related adverse effect: A case report","volume":"10","author":"Edahiro","year":"2019","journal-title":"Thorac Cancer"},{"key":"key20250513102021_b21-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40425-017-0245-2","article-title":"Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer","volume":"5","author":"Godwin","year":"2017","journal-title":"J Immunother Cancer"},{"key":"key20250513102021_b22-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1177\/1078155218816777","article-title":"Nivolumab-induced Acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report","volume":"25","author":"Hatakeyama","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"key20250513102021_b23-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"e25795","DOI":"10.1097\/MD.0000000000025795","article-title":"Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review","volume":"100","author":"Huang","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"key20250513102021_b24-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1507\/endocrj.EJ20-0769","article-title":"Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: A retrospective case series","volume":"68","author":"Ishi","year":"2021","journal-title":"Endocr J"},{"key":"key20250513102021_b25-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"e931702","DOI":"10.12659\/AJCR.931702","article-title":"A severe case of diabetic ketoacidosis and New-onset type 1 diabetes mellitus associated with Anti-glutamic acid decarboxylase antibodies following immunotherapy with pembrolizumab","volume":"22","author":"Kedzior","year":"2021","journal-title":"Am J Case Rep"},{"key":"key20250513102021_b26-ol-29-6-15023","first-page":"18","article-title":"Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy","volume":"2018","author":"Lee","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"key20250513102021_b27-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000456540","article-title":"Autoimmune diabetes and thyroiditis complicating treatment with nivolumab","volume":"10","author":"Li","year":"2017","journal-title":"Case Rep Oncol"},{"key":"key20250513102021_b28-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"379","DOI":"10.21037\/tlcr.2020.03.05","article-title":"Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: A case report and brief review","volume":"9","author":"Li","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"key20250513102021_b29-ol-29-6-15023","first-page":"19","article-title":"Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: Insights from four cases","volume":"2019","author":"Lupi","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"key20250513102021_b30-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"e00685","DOI":"10.1002\/rcr2.685","article-title":"Atezolizumab-induced fulminant type 1 diabetes mellitus occurring four months after treatment cessation","volume":"8","author":"Nishioki","year":"2020","journal-title":"Respirol Case Rep"},{"key":"key20250513102021_b31-ol-29-6-15023","first-page":"19","article-title":"Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism","volume":"2019","author":"Patel","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"key20250513102021_b32-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13256-020-02502-w","article-title":"Pembrolizumab- and Ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: A case report","volume":"14","author":"Porntharukchareon","year":"2020","journal-title":"J Med Case Rep"},{"key":"key20250513102021_b33-ol-29-6-15023","first-page":"61","article-title":"Immune checkpoint inhibitors related diabetes mellitus: A report of 2 cases and literature review","volume":"25","author":"Ren","year":"2022","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"key20250513102021_b34-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"e30456","DOI":"10.1097\/MD.0000000000030456","article-title":"New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report","volume":"101","author":"Seo","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"key20250513102021_b35-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3389\/fendo.2019.00352","article-title":"Atezolizumab-induced autoimmune diabetes in a patient with metastatic lung cancer","volume":"10","author":"Sothornwit","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key20250513102021_b36-ol-29-6-15023","first-page":"18","article-title":"Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis","volume":"2018","author":"Tzoulis","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"key20250513102021_b37-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.12998\/wjcc.v10.i4.1263","article-title":"Sintilimab-induced autoimmune diabetes: A case report and review of the literature","volume":"10","author":"Yang","year":"2022","journal-title":"World J Clin Cases"},{"key":"key20250513102021_b38-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/j.1365-2036.2008.03655.x","article-title":"Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury","volume":"27","author":"Garc\u00eda-Cort\u00e9s","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"key20250513102021_b39-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III Non-Small-Cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"key20250513102021_b40-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"key20250513102021_b41-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"722979","DOI":"10.3389\/fimmu.2021.722979","article-title":"Natural killer cells as key mediators in type i diabetes immunopathology","volume":"12","author":"Gardner","year":"2021","journal-title":"Front Immunol"},{"key":"key20250513102021_b42-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s12020-024-04050-5","article-title":"Pathophysiology, diagnosis, and management of immune checkpoint Inhibitor-induced diabetes mellitus","volume":"87","author":"Kani","year":"2025","journal-title":"Endocrine"},{"key":"key20250513102021_b43-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s12020-024-03942-w","article-title":"Immune checkpoint inhibitors-induced diabetes mellitus (review)","volume":"86","author":"Chen","year":"2024","journal-title":"Endocrine"},{"key":"key20250513102021_b44-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"757","DOI":"10.4093\/dmj.2023.0072","article-title":"Immune-Checkpoint Inhibitors-Induced Type 1 diabetes mellitus: From its molecular mechanisms to clinical practice","volume":"47","author":"Cho","year":"2023","journal-title":"Diabetes Metab J"},{"key":"key20250513102021_b45-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"e156330","DOI":"10.1172\/jci.insight.156330","article-title":"Immune cells and their inflammatory mediators modify \u03b2 cells and cause checkpoint Inhibitor-induced diabetes","volume":"7","author":"Perdigoto","year":"2022","journal-title":"JCI Insight"},{"key":"key20250513102021_b46-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.2337\/dc18-2518","article-title":"T-Lymphocyte infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"key":"key20250513102021_b47-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"764138","DOI":"10.3389\/fendo.2021.764138","article-title":"Unravelling checkpoint inhibitor associated autoimmune diabetes: From bench to bedside","volume":"12","author":"Wu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key20250513102021_b48-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/jdi.14362","article-title":"Immune checkpoint Inhibitor-related type 1 diabetes incidence, risk, and survival association","volume":"16","author":"Kamitani","year":"2025","journal-title":"J Diabetes Investig"},{"key":"key20250513102021_b49-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7861\/clinmed.2020-0054","article-title":"Is immune checkpoint Inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?","volume":"20","author":"Kyriacou","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"key20250513102021_b50-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"620522","DOI":"10.3389\/fendo.2021.620522","article-title":"Coexistence of immune checkpoint inhibitor-induced autoimmune diabetes and pancreatitis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key20250513102021_b51-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"110414","DOI":"10.1016\/j.intimp.2023.110414","article-title":"Recent advances in immune checkpoint Inhibitor-induced type 1 diabetes mellitus","volume":"122","author":"Liao","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"key20250513102021_b52-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.jtho.2016.12.015","article-title":"Association of serum Anti-GAD antibody and HLA haplotypes with type 1 diabetes mellitus triggered by nivolumab in patients with Non-small cell lung cancer","volume":"12","author":"Usui","year":"2017","journal-title":"J Thorac Oncol"},{"key":"key20250513102021_b53-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1590\/S0100-879X1999001000003","article-title":"Frequency of islet cell autoantibodies (IA-2 and GAD) in young Brazilian type 1 diabetes patients","volume":"32","author":"Pardini","year":"1999","journal-title":"Braz J Med Biol Res"},{"key":"key20250513102021_b54-ol-29-6-15023","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13098-024-01263-6","article-title":"Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: Insights into immune checkpoint inhibitors induced diabetes mellitus","volume":"16","author":"Wei","year":"2024","journal-title":"Diabetol Metab Syndr"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:20:30Z","timestamp":1747120830000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":54,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,7]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15023","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]}}}